|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYOM1 |
Gene summary for MYOM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYOM1 | Gene ID | 8736 |
| Gene name | myomesin 1 | |
| Gene Alias | SKELEMIN | |
| Cytomap | 18p11.31 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | P52179 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8736 | MYOM1 | NAFLD1 | Human | Liver | NAFLD | 9.98e-04 | 8.05e-01 | -0.04 |
| 8736 | MYOM1 | HCC1_Meng | Human | Liver | HCC | 1.03e-37 | -3.71e-02 | 0.0246 |
| 8736 | MYOM1 | HCC2_Meng | Human | Liver | HCC | 3.93e-04 | -6.95e-02 | 0.0107 |
| 8736 | MYOM1 | HCC1 | Human | Liver | HCC | 2.04e-04 | 2.93e+00 | 0.5336 |
| 8736 | MYOM1 | S028 | Human | Liver | HCC | 6.41e-06 | 2.89e-01 | 0.2503 |
| 8736 | MYOM1 | S029 | Human | Liver | HCC | 2.52e-03 | 2.81e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512227 | Liver | NAFLD | positive regulation of protein transport | 55/1882 | 303/18723 | 1.07e-05 | 3.35e-04 | 55 |
| GO:19049517 | Liver | NAFLD | positive regulation of establishment of protein localization | 55/1882 | 319/18723 | 4.79e-05 | 1.14e-03 | 55 |
| GO:00355926 | Liver | NAFLD | establishment of protein localization to extracellular region | 52/1882 | 360/18723 | 4.80e-03 | 3.81e-02 | 52 |
| GO:00507147 | Liver | NAFLD | positive regulation of protein secretion | 24/1882 | 137/18723 | 4.89e-03 | 3.85e-02 | 24 |
| GO:00093066 | Liver | NAFLD | protein secretion | 51/1882 | 359/18723 | 7.17e-03 | 4.96e-02 | 51 |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:003559212 | Liver | HCC | establishment of protein localization to extracellular region | 176/7958 | 360/18723 | 7.96e-03 | 3.15e-02 | 176 |
| GO:000930612 | Liver | HCC | protein secretion | 175/7958 | 359/18723 | 9.32e-03 | 3.57e-02 | 175 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYOM1 | SNV | Missense_Mutation | novel | c.3042N>C | p.Met1014Ile | p.M1014I | P52179 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| MYOM1 | SNV | Missense_Mutation | rs755768408 | c.3578N>T | p.Thr1193Met | p.T1193M | P52179 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
| MYOM1 | SNV | Missense_Mutation | rs374904841 | c.4922N>T | p.Ser1641Leu | p.S1641L | P52179 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
| MYOM1 | SNV | Missense_Mutation | c.700G>C | p.Glu234Gln | p.E234Q | P52179 | protein_coding | tolerated(0.06) | probably_damaging(0.959) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MYOM1 | SNV | Missense_Mutation | rs759276149 | c.4654N>A | p.Asp1552Asn | p.D1552N | P52179 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MYOM1 | SNV | Missense_Mutation | c.3841N>C | p.Glu1281Gln | p.E1281Q | P52179 | protein_coding | deleterious(0) | benign(0.105) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MYOM1 | SNV | Missense_Mutation | novel | c.1081N>A | p.Leu361Ile | p.L361I | P52179 | protein_coding | tolerated(0.29) | benign(0.011) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| MYOM1 | SNV | Missense_Mutation | c.1462G>A | p.Glu488Lys | p.E488K | P52179 | protein_coding | tolerated(0.41) | benign(0.243) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| MYOM1 | SNV | Missense_Mutation | c.3856G>A | p.Glu1286Lys | p.E1286K | P52179 | protein_coding | tolerated(0.36) | benign(0.074) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MYOM1 | SNV | Missense_Mutation | c.905G>A | p.Gly302Asp | p.G302D | P52179 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |